We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503.
- Authors
Matsuda, Ayako; Yamaoka, Kazue; Kunitoh, Hideo; Seto, Takashi; Tsuboi, Masahiro; Ohira, Tatsuo; Maruyama, Riichiroh; Okamoto, Hiroaki; Kubota, Kaoru
- Abstract
Purpose: The TORG0503 study was undertaken to select a preferred platinum-based third-generation regimen for patients with completely resected non-small cell lung cancer (NSCLC). This study aimed to describe the quality of life (QOL) analysis of that study. Methods: Patients with completely resected NSCLC were randomized to receive three cycles of docetaxel plus cisplatin (DC) or paclitaxel plus carboplatin (PC) on day 1 every 3 weeks. QOL was assessed at three time points (baseline, after two cycles, and after three cycles) using the Functional Assessment of Cancer Therapy–taxane (FACT-Taxane). The adjusted odds ratio (OR) and 95% confidence interval (CI) were calculated by logistic regression analysis that was adjusted for the baseline score in the FACT-Taxane total score and each subscale to evaluate treatment (PC vs. DC) effectiveness. Results: QOL data from 104 patients (DC, n = 56 patients; PC, n = 48) were analyzed. In the FACT-Taxane total score, the baseline-adjusted OR (95% CI) of not worse QOL for the DC group was 3.3 (1.4–8.3) compared with the PC group. In the taxane subscale, the baseline-adjusted OR (95% CI) was 6.2 (2.6–16.0). Conclusion: Total QOL was maintained better in the DC group than in the PC group, especially the taxane subscale that consists of neurotoxicity and taxane components in spite of no treatment-related death in both arms between DC and PC. We might recommend DC as the control regimen for the next clinical trial from the viewpoint of QOL, similar to the primary outcomes in TORG0503.
- Subjects
CARBOPLATIN; PACLITAXEL; NON-small-cell lung carcinoma; DOCETAXEL; CISPLATIN; QUALITY of life; LOGISTIC regression analysis
- Publication
Quality of Life Research, 2023, Vol 32, Issue 9, p2629
- ISSN
0962-9343
- Publication type
Article
- DOI
10.1007/s11136-023-03424-y